Enzene Biosciences

Enzene Biosciences is a global biotech company and contract development and manufacturing organization (CDMO) that provides services to pharmaceutical companies for drug development and manufacturing processes. The company, a subsidiary of Alkem Laboratories Ltd., focuses on producing biosimilars, novel biologics, synthetic peptides, and phytopharmaceuticals. Enzene's product portfolio includes biosimilars such as Teriparatide for osteoporosis, Cetuximab for head and neck cancer and colorectal cancer, Romiplostim for immune thrombocytopenic purpura, and several others targeting various medical conditions. The company utilizes a cutting-edge continuous manufacturing platform called EnzeneX, which enables streamlined and efficient production processes. In January 2024, Enzene launched its first manufacturing site outside India, located within the Princeton West Innovation Campus in Hopewell, New Jersey. This 55,000-square-foot facility, representing a USD 50 million investment, is expected to be operational in June 2024. The US plant will host multiple manufacturing lines of the EnzeneX platform and aims to cater to small and mid-sized biotech companies, providing them with clinical phase capacity. Enzene plans to seek USDA and USFDA approval for the US facility within a year of its launch. The company's expansion strategy includes gradually expanding operations across five major markets: EU, US, Canada, Australia, and Japan for biologics and biosimilars.

Key customers and partnerships

Enzene Biosciences serves global pharmaceutical companies as its key customers. The company's new US facility is strategically located within easy reach of several global biotech and pharmaceutical firms in the Northeast Corridor. As of January 2024, customers had already started reserving capacities for continuous manufacturing and/or fed-batch processes at the New Jersey plant. Enzene's local manufacturing capabilities in the US aim to provide North American biopharmaceutical companies with streamlined supply chains, fast turnaround times, enhanced communication, and greater control over the manufacturing process. The company's expansion into New Jersey is expected to enable it to attract top talent and forge valuable partnerships to expedite its contract manufacturing capabilities.